Cargando…

Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases

Camelids produce both conventional heterotetrameric antibodies and homodimeric heavy-chain only antibodies. The antigen-binding region of such homodimeric heavy-chain only antibodies consists of one single domain, called VHH. VHHs provide many advantages over conventional full-sized antibodies and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lafaye, Pierre, Li, Tengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112682/
https://www.ncbi.nlm.nih.gov/pubmed/30396425
http://dx.doi.org/10.1016/j.cimid.2018.09.009
_version_ 1783513521508581376
author Lafaye, Pierre
Li, Tengfei
author_facet Lafaye, Pierre
Li, Tengfei
author_sort Lafaye, Pierre
collection PubMed
description Camelids produce both conventional heterotetrameric antibodies and homodimeric heavy-chain only antibodies. The antigen-binding region of such homodimeric heavy-chain only antibodies consists of one single domain, called VHH. VHHs provide many advantages over conventional full-sized antibodies and currently used antibody-based fragments (Fab, scFv), including high specificity, stability and solubility, and small size, allowing them to recognize unusual antigenic sites and deeply penetrate tissues. Since their discovery, VHHs have been used extensively in diagnostics and therapy. In recent decades, the number of outbreaks of diseases transmissible from animals to humans has been on the rise. In this review, we evaluate the status of VHHs as diagnostic and therapeutic biomolecular agents for the detection and treatment of zoonotic diseases, such as bacterial, parasitic, and viral zoonosis. VHHs show great adaptability to inhibit or neutralize pathogenic agents for the creation of multifunctional VHH-based diagnostic and therapeutic molecules against zoonotic diseases.
format Online
Article
Text
id pubmed-7112682
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71126822020-04-02 Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases Lafaye, Pierre Li, Tengfei Comp Immunol Microbiol Infect Dis Article Camelids produce both conventional heterotetrameric antibodies and homodimeric heavy-chain only antibodies. The antigen-binding region of such homodimeric heavy-chain only antibodies consists of one single domain, called VHH. VHHs provide many advantages over conventional full-sized antibodies and currently used antibody-based fragments (Fab, scFv), including high specificity, stability and solubility, and small size, allowing them to recognize unusual antigenic sites and deeply penetrate tissues. Since their discovery, VHHs have been used extensively in diagnostics and therapy. In recent decades, the number of outbreaks of diseases transmissible from animals to humans has been on the rise. In this review, we evaluate the status of VHHs as diagnostic and therapeutic biomolecular agents for the detection and treatment of zoonotic diseases, such as bacterial, parasitic, and viral zoonosis. VHHs show great adaptability to inhibit or neutralize pathogenic agents for the creation of multifunctional VHH-based diagnostic and therapeutic molecules against zoonotic diseases. Elsevier Ltd. 2018-10 2018-09-25 /pmc/articles/PMC7112682/ /pubmed/30396425 http://dx.doi.org/10.1016/j.cimid.2018.09.009 Text en © 2018 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Lafaye, Pierre
Li, Tengfei
Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases
title Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases
title_full Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases
title_fullStr Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases
title_full_unstemmed Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases
title_short Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases
title_sort use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112682/
https://www.ncbi.nlm.nih.gov/pubmed/30396425
http://dx.doi.org/10.1016/j.cimid.2018.09.009
work_keys_str_mv AT lafayepierre useofcamelsingledomainantibodiesforthediagnosisandtreatmentofzoonoticdiseases
AT litengfei useofcamelsingledomainantibodiesforthediagnosisandtreatmentofzoonoticdiseases